MDT-AP-0441
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- M
- new_clusters
- C3
- umap1_2d
- 6.096602818
- umap2_2d
- 4.33401823
- umap1_3d
- 3.227058938
- umap2_3d
- -1.618945877
- umap3_3d
- -2.107979489
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- HEME_METABOLISM+0.210
- MITOTIC_SPINDLE+0.190
- ANDROGEN_RESPONSE+0.100
- PANCREAS_BETA_CELLS+0.090
- PI3K_AKT_MTOR_SIGNALING+0.080
- TGF_BETA_SIGNALING+0.080
- SPERMATOGENESIS+0.070
- KRAS_SIGNALING_UP+0.040
- PEROXISOME+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- MYC_TARGETS_V2-0.380
- ANGIOGENESIS-0.370
- E2F_TARGETS-0.370
- INTERFERON_ALPHA_RESPONSE-0.340
- MYOGENESIS-0.320
- UV_RESPONSE_UP-0.320
- APICAL_JUNCTION-0.310
- MYC_TARGETS_V1-0.310
- OXIDATIVE_PHOSPHORYLATION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R141 | — | — | 0.831 |
| 2 | TCGA-44-5645-01A-01R-A278-07 | — | cohortMD2 | 0.820 |
| 3 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.804 |
| 4 | MDT-AP-2993 | Med | Medulloblastoma | 0.802 |
| 5 | MDT-AP-3269 | Med | Medulloblastoma | 0.801 |
| 6 | MDT-AP-2991 | Med | Medulloblastoma | 0.796 |
| 7 | BS_HTEPAKCM | Med | Medulloblastoma | 0.794 |
| 8 | TCGA-AC-A3OD-01A-11R-A21T-07 | — | D | 0.780 |
| 9 | BS_5PJCHF6V | Med | Medulloblastoma | 0.778 |
| 10 | SJEPD030399_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.020 | Idelalisib | — uncovered |